Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology October 1, 2007 Martina Ballmaier, Marco Bortolato, Cristina Rizzetti et al.
Clinical and laboratory findings suggest that cannabinoids and their receptors are implicated in schizophrenia. The role of cannabinoids in schizophrenia remains however poorly understood, as data are often contradictory. The primary aim of this study was to investigate whether the cannabinoid CB1 receptor antagonists rimonabant and AM251 are able to reverse deficits of sensorimotor gating...